

Central Nervous System Diseases

The development of new treatment options for Neuropsychiatric diseases is a key priority for Boehringer Ingelheim, evidenced by the innovative work in these areas of both its collaboration partners and the Company's own highly experienced research and development professionals.

Indications:

Neuropsychiatric diseases including:

- Alzheimer's disease (focus: cognitive impairment and other neuropsychiatric symptoms)
- Schizophrenia (focus: negative symptoms and/or cognitive impairment)
- Depression (focus: treatment-resistant depression)
- Impulse control disorders.

Specific partnering priorities:

- Novel approaches to modulate fundamental mechanisms and pathways involved in synaptic dysfunction and maladaptive brain circuitry as the root causes of various neuropsychiatric symptom domains; ideally, the proposed modality will include a target engagement and/or pharmacodynamic marker
- Complementary non-drug approaches (e.g. cognitive remediation).

In all these areas, we are looking for compounds and concepts from early drug discovery to pre-clinical and early clinical stages.

Out of scope:

- Neuroprotective agents
- Monoamine uptake inhibitors or monoamine receptor modulators
- Compounds with unknown mechanism of action.

If you share our goal of researching and developing new medications to improve the health of people around the world please join us in...

Working together
for better health

For more information please contact our BD&L team:

Klaus D. Mendla, PhD

klaus.mendla@boehringer-ingelheim.com

Laura Corradini, PhD

laura.corradini@boehringer-ingelheim.com

